HK1011925A1 - Use of thiazolidiones to prevent or delay onset ofniddm - Google Patents

Use of thiazolidiones to prevent or delay onset ofniddm

Info

Publication number
HK1011925A1
HK1011925A1 HK98113005A HK98113005A HK1011925A1 HK 1011925 A1 HK1011925 A1 HK 1011925A1 HK 98113005 A HK98113005 A HK 98113005A HK 98113005 A HK98113005 A HK 98113005A HK 1011925 A1 HK1011925 A1 HK 1011925A1
Authority
HK
Hong Kong
Prior art keywords
prevent
thiazolidiones
ofniddm
delay onset
onset
Prior art date
Application number
HK98113005A
Other languages
English (en)
Inventor
Jerrold Olefsky
Tammy Antonucci
Dean Lockwood
Rebecca Norris
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08293899 external-priority patent/US5478852C1/en
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Priority to HK06106673.5A priority Critical patent/HK1085134A1/xx
Publication of HK1011925A1 publication Critical patent/HK1011925A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK98113005A 1993-09-15 1998-12-09 Use of thiazolidiones to prevent or delay onset ofniddm HK1011925A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
HK06106673.5A HK1085134A1 (en) 1993-09-15 1998-12-09 Use of thiazolidinediones to prevent or delay onset of niddm

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12225193A 1993-09-15 1993-09-15
US08293899 US5478852C1 (en) 1993-09-15 1994-08-23 Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
PCT/US1994/010389 WO1995007694A1 (en) 1993-09-15 1994-09-14 Use of thiazolidinediones to prevent or delay onset of niddm

Publications (1)

Publication Number Publication Date
HK1011925A1 true HK1011925A1 (en) 1999-07-23

Family

ID=26820333

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98113005A HK1011925A1 (en) 1993-09-15 1998-12-09 Use of thiazolidiones to prevent or delay onset ofniddm

Country Status (16)

Country Link
EP (2) EP0719140B1 (xx)
JP (3) JP3081245B2 (xx)
CN (3) CN1103590C (xx)
AT (1) ATE376829T1 (xx)
AU (3) AU679572B2 (xx)
CA (1) CA2171827C (xx)
CZ (1) CZ283339B6 (xx)
DK (1) DK0719140T3 (xx)
ES (1) ES2296288T3 (xx)
FI (1) FI961213A (xx)
HK (1) HK1011925A1 (xx)
HU (1) HU228260B1 (xx)
NO (3) NO310097B1 (xx)
NZ (1) NZ274346A (xx)
RU (1) RU2195282C2 (xx)
WO (1) WO1995007694A1 (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874454A (en) * 1993-09-15 1999-02-23 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
AU2381397A (en) * 1996-04-19 1997-11-12 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
EP0930882A2 (en) * 1996-08-02 1999-07-28 Institut Pasteur De Lille Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
DE69738809D1 (de) * 1996-11-08 2008-08-14 Nippon Chemiphar Co Mittel zur verringerung der eigeweidefette
AU754479B2 (en) * 1997-05-15 2002-11-14 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
GB9712866D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
HUP9902721A2 (hu) 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
AU2002314744A1 (en) 2001-04-17 2002-10-28 Sepracor, Inc. Thiazole and other heterocyclic ligands and use thereof
US6531461B1 (en) * 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
US6794401B2 (en) * 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
MXPA05007883A (es) 2003-01-29 2005-09-21 Takeda Pharmaceutical Proceso para producir una preparacion recubierta.
JP4567340B2 (ja) * 2003-01-29 2010-10-20 武田薬品工業株式会社 被覆製剤の製造方法
ZA200506397B (en) * 2003-01-29 2006-11-29 Takeda Pharmaceutical Process for producing coated preparation
FR2858321B1 (fr) * 2003-07-28 2006-01-20 Servier Lab Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2006080524A1 (ja) * 2005-01-31 2006-08-03 Ajinomoto Co., Inc. 血糖降下剤を含有する、耐糖能異常、境界型糖尿病、インスリン抵抗性及び高インスリン血症の改善ないし治療用医薬組成物
PL2902026T3 (pl) * 2006-03-16 2018-03-30 Metabolic Solutions Development Company Llc Analogi tiazolidynodionu do leczenia choroby metabolicznej pośredniczonej przez zapalenie

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4873255A (en) * 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group Plc Substituierte Thiazolidindionderivate
US5061717A (en) * 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US4897405A (en) * 1989-04-21 1990-01-30 American Home Products Corporation Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
GB8919434D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
JP2826379B2 (ja) * 1990-01-22 1998-11-18 三共株式会社 チアゾリジン誘導体を有効成分とする肥満性高血圧症治療剤
GB9023583D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9023585D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
ATE142631T1 (de) * 1991-06-25 1996-09-15 Pfizer Thiazolidindione als hypoglykämische wirkstoffe
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2688220A1 (fr) * 1992-03-06 1993-09-10 Adir Nouveaux derives de thiazolidine-2,4-dione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
AU1770997A (en) 1997-05-29
HU9600653D0 (en) 1996-05-28
CN1202821C (zh) 2005-05-25
ATE376829T1 (de) 2007-11-15
EP1714652A3 (en) 2007-01-17
WO1995007694A1 (en) 1995-03-23
CN1202823C (zh) 2005-05-25
NO314748B1 (no) 2003-05-19
NO310097B1 (no) 2001-05-21
EP0719140A4 (en) 2001-08-16
CN1134669A (zh) 1996-10-30
NO20002964D0 (no) 2000-06-09
CN1387849A (zh) 2003-01-01
CN1103590C (zh) 2003-03-26
JPH09502727A (ja) 1997-03-18
JP2000273043A (ja) 2000-10-03
CZ79396A3 (en) 1996-10-16
CZ283339B6 (cs) 1998-03-18
NO961041L (no) 1996-05-14
AU706947B2 (en) 1999-07-01
NZ274346A (en) 1997-06-24
EP0719140B1 (en) 2007-10-31
NO20002963D0 (no) 2000-06-09
CA2171827A1 (en) 1995-03-23
AU7835194A (en) 1995-04-03
FI961213A (fi) 1996-05-14
JP2000239167A (ja) 2000-09-05
CN1387848A (zh) 2003-01-01
DK0719140T3 (da) 2008-03-03
HUT75874A (en) 1997-05-28
NO2963A (no) 1996-05-14
NO2964A (no) 1996-05-14
NO961041D0 (no) 1996-03-14
HU228260B1 (en) 2013-02-28
JP3081245B2 (ja) 2000-08-28
AU679572B2 (en) 1997-07-03
NO314747B1 (no) 2003-05-19
AU1771097A (en) 1997-05-29
EP0719140A1 (en) 1996-07-03
CA2171827C (en) 2004-06-29
RU2195282C2 (ru) 2002-12-27
ES2296288T3 (es) 2008-04-16
EP1714652A2 (en) 2006-10-25
FI961213A0 (fi) 1996-03-15

Similar Documents

Publication Publication Date Title
HK1011925A1 (en) Use of thiazolidiones to prevent or delay onset ofniddm
WO1995007697A3 (en) Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
PL348773A1 (en) Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
AU4714393A (en) Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity
CA2179584A1 (en) Pharmaceutical composition containing insulin sensitivity enhancer in combination with another antidiabetic
CA2071629A1 (en) Use of insulin sensitizing agents to treat hypertension
AU3074289A (en) 2,2'-iminobisethanol derivatives as potentiators of the effects of blood pressure reducing agents
CA2294582A1 (en) Treatment of diabetes with thiazolidinedione and metformin
AU2401988A (en) Aqueous finishing agent and process for a soft hand, water and oil repellent treatment of fibrous materials
HU9400350D0 (en) Retard peptides
AU4534793A (en) Combinations of viscoelastics for use during surgery
ZA891681B (en) Thiazolidinedione derivatives as hypoglycemic agents
AU8107694A (en) Use of substituted thiazolidine derivatives in the treatment of raised intraocular pressure
MX9602614A (es) Metodo para formar un articulo absorbente.
AU4815890A (en) Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
EP0462075A3 (en) Use of uridine in the pharmacological treatment of the peripheral complications of diabetes
AU1405595A (en) Use of thalidomide for the treatment of non-insulin dependent diabetes mellitus
PH30179A (en) Antidiabetic agent and method of treating diabetes
GR3018651T3 (en) Treatment of ocular hypertention with a synergistic combination
AU6873491A (en) Glycyl-p-amino-pyridine for the treatment of senile dementia states
GB2224442B (en) Use of a fogging composition for controlling microorganisms on potatoes
EP0092386A3 (en) Hydantoin therapeutic agents
Lekan CORONA TREATMENT AS AN ADHESION PROMOTER FOR UV-/EB-CURABLE COATINGS
EP0337333A3 (en) Process and composition for treating used and soiled electronical or electromechanical parts
SI0869785T1 (en) 4-hydroxycoumarin-3-carboxamides for the treatment of non-insulin dependent diabetes mellitus

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20140913